Oncology & Cancer

Modeling tumor dormancy

Cancer constantly wages war on the human body. Battles are won, lost or sometimes end in a stalemate. In pancreatic cancer, this stalemate—known as tumor dormancy—can last up to 25 years before becoming aggressively malignant, ...

Oncology & Cancer

Corticorelin acetate has steroid-sparing effect in brain cancer

(HealthDay)—Corticorelin acetate (CrA) administration to patients with peritumoral brain edema (PBE) allows the reduction of steroid doses and is associated with reduced incidence and severity of steroid-induced myopathy ...

Oncology & Cancer

Novel immune inhibitor associated with glioma progression

Northwestern Medicine investigators led by Amy Heimberger, MD, Ph.D., the Jean Malnati Miller Professor of Brain Tumor Research and vice chair for Research in the Department of Neurological Surgery, have discovered a new ...

Oncology & Cancer

Immune cell receptor provides promising immunotherapy target

Drugs that target a receptor on immune cells called activin receptor 1C may combat tumor-induced immune suppression and help patients' immune systems fight back against cancer, according to a study by investigators at the ...

page 5 from 6